- Home
- BRNS vs FSEA Comparison
BRNS vs FSEA Comparison
Compare BRNS & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- FSEA
- Stock Information
- Founded
- BRNS 2016
- FSEA 1890
- Country
- BRNS United Kingdom
- FSEA United States
- Employees
- BRNS N/A
- FSEA N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- FSEA Savings Institutions
- Sector
- BRNS Health Care
- FSEA Finance
- Exchange
- BRNS Nasdaq
- FSEA Nasdaq
- Market Cap
- BRNS 48.3M
- FSEA 53.7M
- IPO Year
- BRNS 2021
- FSEA N/A
- Fundamental
- Price
- BRNS $1.05
- FSEA $11.55
- Analyst Decision
- BRNS Strong Buy
- FSEA
- Analyst Count
- BRNS 1
- FSEA 0
- Target Price
- BRNS $3.00
- FSEA N/A
- AVG Volume (30 Days)
- BRNS 37.7K
- FSEA 2.9K
- Earning Date
- BRNS 11-05-2025
- FSEA 11-07-2025
- Dividend Yield
- BRNS N/A
- FSEA N/A
- EPS Growth
- BRNS N/A
- FSEA N/A
- EPS
- BRNS N/A
- FSEA N/A
- Revenue
- BRNS $14,969,000.00
- FSEA $14,095,000.00
- Revenue This Year
- BRNS N/A
- FSEA N/A
- Revenue Next Year
- BRNS N/A
- FSEA N/A
- P/E Ratio
- BRNS N/A
- FSEA N/A
- Revenue Growth
- BRNS 1766.46
- FSEA 30.26
- 52 Week Low
- BRNS $0.64
- FSEA $8.90
- 52 Week High
- BRNS $2.92
- FSEA $11.95
- Technical
- Relative Strength Index (RSI)
- BRNS 40.11
- FSEA 51.06
- Support Level
- BRNS $1.08
- FSEA $11.51
- Resistance Level
- BRNS $1.20
- FSEA $11.74
- Average True Range (ATR)
- BRNS 0.09
- FSEA 0.14
- MACD
- BRNS -0.01
- FSEA -0.01
- Stochastic Oscillator
- BRNS 0.00
- FSEA 22.93
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.